Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Thyroid Gland Carcinoma”

115 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 115 results

Testing effectiveness (Phase 2)Study completedNCT05175404
What this trial is testing

Use of 18F-PSMA-11 PET for Detection of Lesions in Iodine Refractory Thyroid Cancers

Who this might be right for
Thyroid Cancer
University Hospital, Ghent 8
Early research (Phase 1)Study completedNCT05410821
What this trial is testing

Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid Cancer

Who this might be right for
Refractory Thyroid Gland CarcinomaRefractory Thyroid Gland Papillary CarcinomaRefractory Thyroid Gland Follicular Carcinoma+1 more
The First Affiliated Hospital of Xiamen University 12
Early research (Phase 1)Study completedNCT01413113
What this trial is testing

Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery

Who this might be right for
Recurrent Thyroid CancerStage IVA Follicular Thyroid CancerStage IVA Papillary Thyroid Cancer+4 more
University of Washington 6
Not applicableStudy completedNCT00970359
What this trial is testing

Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244

Who this might be right for
Thyroid Cancer
Memorial Sloan Kettering Cancer Center 24
Testing effectiveness (Phase 2)Ended earlyNCT02472080
What this trial is testing

Gemcitabine - Oxaliplatin for Advanced Refractory Thyroid Cancer Patients: a Phase II Study

Who this might be right for
Thyroid Cancer
Assistance Publique - Hôpitaux de Paris 21
Not applicableStudy completedNCT03363347
What this trial is testing

BRAF V600E and Redifferentiation Therapy in Radioiodine-refractory Papillary Thyroid Cancer

Who this might be right for
Thyroid Cancer
Heidelberg University 25
Testing effectiveness (Phase 2)Active Not RecruitingNCT04560127
What this trial is testing

Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer

Who this might be right for
Radioactive Iodine-refractory Differentiated Thyroid Cancer
Peking Union Medical College Hospital 20
Testing effectiveness (Phase 2)Study completedNCT00381641
What this trial is testing

Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery

Who this might be right for
Differentiated Thyroid Gland CarcinomaRecurrent Thyroid Gland CarcinomaRefractory Thyroid Gland Carcinoma+16 more
National Cancer Institute (NCI) 63
Testing effectiveness (Phase 2)Study completedNCT02432274
What this trial is testing

Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma

Who this might be right for
TumorsSolid Malignant TumorsOsteosarcoma+1 more
Eisai Limited 117
Not applicableUnknownNCT06062563
What this trial is testing

Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer

Who this might be right for
Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma
Peking Union Medical College Hospital 10
Testing effectiveness (Phase 2)Study completedNCT03244956
What this trial is testing

Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer

Who this might be right for
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
Gustave Roussy, Cancer Campus, Grand Paris 40
Not applicableApproved For MarketingNCT02211222
What this trial is testing

An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Cancer
Eisai Inc.
Early research (Phase 1)Study completedNCT02456701
What this trial is testing

Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379

Who this might be right for
Thyroid Cancer
Celldex Therapeutics 7
Testing effectiveness (Phase 2)UnknownNCT03732495
What this trial is testing

Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas

Who this might be right for
Thyroid Cancer Metastatic
Centre Leon Berard 35
Early research (Phase 1)Looking for participantsNCT04119024
What this trial is testing

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Who this might be right for
Metastatic Malignant Solid NeoplasmMetastatic MelanomaPathologic Stage IIIC Cutaneous Melanoma AJCC v8+14 more
Anusha Kalbasi 18
Early research (Phase 1)Study completedNCT01709435
What this trial is testing

Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors

Who this might be right for
Recurrent Malignant Solid NeoplasmRecurrent MelanomaRecurrent Primary Central Nervous System Neoplasm+4 more
National Cancer Institute (NCI) 41
Testing effectiveness (Phase 2)Study completedNCT02614495
What this trial is testing

Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma

Who this might be right for
Thyroid Carcinoma
Hutchison Medipharma Limited 66
Testing effectiveness (Phase 2)Study completedNCT02731352
What this trial is testing

Study of Apatinib in Patients With Differentiated Thyroid Cancer

Who this might be right for
Thyroid Cancer
Peking Union Medical College Hospital 20
Testing effectiveness (Phase 2)Study completedNCT00784303
What this trial is testing

Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology

Who this might be right for
Thyroid Cancer
Eisai Inc. 117
Not applicableUnknownNCT02156362
What this trial is testing

Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis)

Who this might be right for
Thyroid Cancer
Hospices Civils de Lyon 643
Load More Results